Supporting Information

Bassani-Sternberg et al. 10.1073/pnas.1008501107



Fig. S1. Correlation of microcapillary chromatography μLC-MS signal intensities of soluble HLA peptides isolated from the growth medium and of membranal HLA peptides isolated from the multiple myeloma cell lines U266 (*A*), L363 (*B*), and RPMI8226 (*C*). High-score identified peptides with Pep-Miner score above 85 are indicated with □; intermediate-score peptides with Pep-Miner score of 70–85 are indicated with +.



Fig. S2. Gene ontology analysis of biological processes of the proteins of origin of the soluble HLA (sHLA) peptides isolated from plasma samples of healthy 1, multiple myeloma 1, multiple myeloma 2, and acute myeloid leukemia 1 (AML-1) (*A*), and comparison between sHLA peptides and membranal HLA peptides from AML-1 (*B*).

Table S1. Clinical features of multiple myeloma, acute myeloid leukemia, and acute lymphoblastic leukemia patients and healthy controls

Table S1 (DOC)

Table S2. The plasma soluble HLA peptidome of multiple myeloma, acute myeloid leukemia, and acute lymphoblastic leukemia patients and healthy controls

Table S2 (XLS)

Table S3. The plasma soluble HLA and membranal HLA peptidomes of acute myeloid leukemia and acute lymphoblastic leukemia patients

Table S3 (XLS)

Table S4. Soluble HLA peptidomes from plasma of healthy controls isolated from blood samples taken on separate days

Table S4 (XLS)

Table S5. Example of peptides originating from plasma proteins, identified among the immunoaffinity purified soluble HLA peptides collected from the donor's plasma

Table S5 (DOC)

Table S6. Similarities between the soluble HLA and membranal HLA peptidomes of cultured cell lines

Table S6 (XLS)

Table S7. The soluble HLA and membranal HLA peptidomes of three multiple myeloma cultured cell lines

Table S7 (XLS)

Table S8. Similarity between soluble HLA peptidomes identified in the plasma samples of different donors

Table S8 (DOC)